Viewing Study NCT07218003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:12 PM
Ignite Modification Date: 2026-03-02 @ 5:53 PM
Study NCT ID: NCT07218003
Status: RECRUITING
Last Update Posted: 2025-10-24
First Post: 2025-10-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Sponsor: Rondo Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Cancer View
None Cervical Cancer View
None Head and Neck Squamous Cell Cancer View
None Triple Negative Breast Cancer (TNBC) View
None Urothelial Carcinoma Bladder View
None Gastroesophageal Junction (GEJ) Adenocarcinoma View
None Esophageal Squamous Cell Cancer View
None Gastric Cancer View
None Cancer View
None Solid Tumors (Phase 1) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None RNDO-564-001 View
None bladder cancer View
None bispecific antibody View
None solid tumors View
None Nectin-4 View
None dose escalation View
None Phase 1/1b View
None CD28 x Nectin-4 bispecific View
None T-cell engager View
None CD28 costimulation View